WALD
Waldencast plc1.9400
+0.0400+2.11%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
246.90MP/E (TTM)
-Basic EPS (TTM)
-1.81Dividend Yield
0%Recent Filings
8-K
Shareholders approve Obagi-Milk merger
Waldencast shareholders overwhelmingly approved the business combination with Obagi Skincare and Milk Makeup at the July 25, 2022 extraordinary general meeting, with 98% support from 70% of outstanding shares. The deal, including domestication to Waldencast plc in Jersey and adoption of a 2022 Incentive Award Plan reserving 15% of post-combination shares, sets the stage for a multi-brand beauty platform. Closing expected July 27, 2022. Yet 30 million shares redeemed, trimming cash infusion.
8-K
Waldencast boosts PIPE to $118M
Waldencast Acquisition Corp. secured a $5 million PIPE investment from new investors, issuing 500,000 shares at $10 each, boosting total PIPE funding to $118 million for its impending business combination with Obagi and Milk. The deal, set to close around July 27, 2022, includes a $450,000 interest-free working capital loan from its sponsor to bridge operations until then. Waldencast shifted its Nasdaq listing application to the Capital Market tier while keeping symbols intact. Yet Nasdaq approval remains a key hurdle.
8-K
Waldencast analyst update on mergers
Waldencast kicked off analyst meetings on July 1, 2022, unveiling slides on its pending merger with Obagi and acquisition of Milk Makeup. The deals imply a $1.2 billion pro forma enterprise value, with $113 million PIPE funding and up to $333 million from FPAs, while securing a $175 million term loan and $50 million revolver for growth. Obagi and Milk shareholders retain 18% and 14% ownership, respectively. Yet redemptions could slash cash to balance sheet.
8-K
Waldencast secures merger financing
Waldencast Acquisition Corp. secured a $175 million term loan and $50 million revolving facility on June 24, 2022, at roughly half the cost of prior debt, signaling lender confidence ahead of its mergers with Obagi and Milk. Proceeds will fund transaction consideration, repay existing credit agreements, and support working capital. This financing, combined with $113 million in PIPE commitments and $333 million in forward purchase agreements, could deliver up to $1.016 billion if no redemptions occur. Yet risks loom if shareholder approval falters.
8-K
Merger adjustments and PIPE boost
Waldencast Acquisition Corp. signed a conditional consent on June 13, 2022, adjusting its merger with Obagi by deducting unpaid inventory costs from Cedarwalk's cash consideration, while settling intercompany debts and imposing a 2.75% royalty on specific sales for 90 days post-closing. It also secured an additional $8 million PIPE investment from new investors, bringing total commitments to $113 million. CFO Tassilo Festetics resigned effective June 10, with Michel Brousset stepping in as principal financial officer. Yet the merger's completion hinges on shareholder approval.
IPO
Website
Employees
Sector
Industry
COTY
Coty Inc.
3.27-0.01
EL
Estee Lauder Companies, Inc. (T
104.39+3.36
ELF
e.l.f. Beauty, Inc.
78.77+0.17
HELE
Helen of Troy Limited
20.35-0.54
HNST
The Honest Company, Inc.
2.86+0.05
NUS
Nu Skin Enterprises, Inc.
10.51+0.01
PG
Procter & Gamble Company (The)
145.21+0.08
SKIN
The Beauty Health Company
1.41+0.03
UL
Unilever PLC
64.33-0.71
XAGE
Longevity Health Holdings, Inc.
0.44-0.05